<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">27141051</PMID>
      <DateCompleted>
        <Year>2017</Year>
        <Month>10</Month>
        <Day>03</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>08</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1943-0264</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>8</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>2016</Year>
              <Month>May</Month>
              <Day>02</Day>
            </PubDate>
          </JournalIssue>
          <Title>Cold Spring Harbor perspectives in biology</Title>
          <ISOAbbreviation>Cold Spring Harb Perspect Biol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>TGF-β and the TGF-β Family: Context-Dependent Roles in Cell and Tissue Physiology.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">a021873</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1101/cshperspect.a021873</ELocationID>
        <Abstract>
          <AbstractText>The transforming growth factor-β (TGF-β) is the prototype of the TGF-β family of growth and differentiation factors, which is encoded by 33 genes in mammals and comprises homo- and heterodimers. This review introduces the reader to the TGF-β family with its complexity of names and biological activities. It also introduces TGF-β as the best-studied factor among the TGF-β family proteins, with its diversity of roles in the control of cell proliferation and differentiation, wound healing and immune system, and its key roles in pathology, for example, skeletal diseases, fibrosis, and cancer.</AbstractText>
          <CopyrightInformation>Copyright © 2016 Cold Spring Harbor Laboratory Press; all rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Morikawa</LastName>
            <ForeName>Masato</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Ludwig Cancer Research, Science for Life Laboratory, Uppsala University, Biomedical Center, SE-751 24 Uppsala, Sweden.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Derynck</LastName>
            <ForeName>Rik</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cell and Tissue Biology, University of California at San Francisco, San Francisco, California 94143.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Miyazono</LastName>
            <ForeName>Kohei</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Molecular Pathology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo 113-0033, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2016</Year>
          <Month>05</Month>
          <Day>02</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Cold Spring Harb Perspect Biol</MedlineTA>
        <NlmUniqueID>101513680</NlmUniqueID>
        <ISSNLinking>1943-0264</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016212">Transforming Growth Factor beta</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002454" MajorTopicYN="N">Cell Differentiation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005355" MajorTopicYN="N">Fibrosis</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007107" MajorTopicYN="N">Immune System</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010802" MajorTopicYN="N">Phylogeny</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009626" MajorTopicYN="N">Terminology as Topic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016212" MajorTopicYN="N">Transforming Growth Factor beta</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014945" MajorTopicYN="N">Wound Healing</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2016</Year>
          <Month>5</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2016</Year>
          <Month>5</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2017</Year>
          <Month>10</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">27141051</ArticleId>
        <ArticleId IdType="pmc">PMC4852809</ArticleId>
        <ArticleId IdType="doi">10.1101/cshperspect.a021873</ArticleId>
        <ArticleId IdType="pii">8/5/a021873</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Akhurst RJ. 2012. 
The paradoxical TGF-β vasculopathies. Nat Genet
44: 838–839.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3543110</ArticleId>
            <ArticleId IdType="pubmed">22836090</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Amendt C, Mann A, Schirmacher P, Blessing M. 2002. 
Resistance of keratinocytes to TGFβ-mediated growth restriction and apoptosis induction accelerates re-epithelialization in skin wounds. J Cell Sci
115: 2189–2198.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11973359</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Andersson O, Korach-Andre M, Reissmann E, Ibanez CF, Bertolino P. 2008. 
Growth/differentiation factor 3 signals through ALK7 and regulates accumulation of adipose tissue and diet-induced obesity. Proc Natl Acad Sci
105: 7252–7256.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2438236</ArticleId>
            <ArticleId IdType="pubmed">18480259</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Andriopoulos B Jr, Corradini E, Xia Y, Faasse SA, Chen S, Grgurevic L, Knutson MD, Pietrangelo A, Vukicevic S, Lin HY, et al.
2009. 
BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism. Nat Genet
41: 482–487.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2810136</ArticleId>
            <ArticleId IdType="pubmed">19252486</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anido J, Saez-Borderias A, Gonzalez-Junca A, Rodon L, Folch G, Carmona MA, Prieto-Sanchez RM, Barba I, Martinez-Saez E, Prudkin L, et al.
2010. 
TGF-β receptor inhibitors target the CD44high/Id1high glioma-initiating cell population in human glioblastoma. Cancer Cell
18: 655–668.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21156287</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Annes JP, Chen Y, Munger JS, Rifkin DB. 2004. 
Integrin αVβ6-mediated activation of latent TGF-β requires the latent TGF-β binding protein-1. J Cell Biol
165: 723–734.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2172370</ArticleId>
            <ArticleId IdType="pubmed">15184403</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anzano MA, Roberts AB, Sporn MB. 1986. 
Anchorage-independent growth of primary rat embryo cells is induced by platelet-derived growth factor and inhibited by type-β transforming growth factor. J Cell Physiol
126: 312–318.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3455929</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aono A, Hazama M, Notoya K, Taketomi S, Yamasaki H, Tsukuda R, Sasaki S, Fujisawa Y. 1995. 
Potent ectopic bone-inducing activity of bone morphogenetic protein-4/7 heterodimer. Biochem Biophys Res Commun
210: 670–677.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7763240</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Asashima M, Nakano H, Shimada K, Kinoshita K, Ishii K, Shibai H, Ueno N. 1990. 
Mesodermal induction in early amphibian embryos by activin A (erythroid differentiation factor). Rouxs Arch Dev Biol
198: 330–335.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28305412</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ashcroft GS, Yang X, Glick AB, Weinstein M, Letterio JL, Mizel DE, Anzano M, Greenwell-Wild T, Wahl SM, Deng C, et al.
1999. 
Mice lacking Smad3 show accelerated wound healing and an impaired local inflammatory response. Nat Cell Biol
1: 260–266.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10559937</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Assoian RK, Komoriya A, Meyers CA, Miller DM, Sporn MB. 1983. 
Transforming growth factor-β in human platelets. Identification of a major storage site, purification, and characterization. J Biol Chem
258: 7155–7160.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6602130</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Beattie GM, Lopez AD, Bucay N, Hinton A, Firpo MT, King CC, Hayek A. 2005. 
Activin A maintains pluripotency of human embryonic stem cells in the absence of feeder layers. Stem Cells
23: 489–495.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15790770</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Behringer RR, Finegold MJ, Cate RL. 1994. 
Müllerian-inhibiting substance function during mammalian sexual development. Cell
79: 415–425.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7954809</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bertoli-Avella AM, Gillis E, Morisaki H, Verhagen JM, de Graaf BM, van de Beek G, Gallo E, Kruithof BP, Venselaar H, Myers LA, et al.
2015. 
Mutations in a TGF-β ligand, TGFB3, cause syndromic aortic aneurysms and dissections. J Am Coll Cardiol
65: 1324–1336.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4380321</ArticleId>
            <ArticleId IdType="pubmed">25835445</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bierie B, Moses HL. 2006. 
TGFβ: The molecular Jekyll and Hyde of cancer. Nat Rev Cancer
6: 506–520.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16794634</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blahna MT, Hata A. 2013. 
Regulation of miRNA biogenesis as an integrated component of growth factor signaling. Curr Opin Cell Biol
25: 233–240.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4429755</ArticleId>
            <ArticleId IdType="pubmed">23312066</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blank U, Karlsson S. 2015. 
TGF-β signaling in the control of hematopoietic stem cells. Blood
125: 3542–3550.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25833962</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boileau C, Guo DC, Hanna N, Regalado ES, Detaint D, Gong L, Varret M, Prakash SK, Li AH, d’Indy H, et al.
2012. 
TGFB2 mutations cause familial thoracic aortic aneurysms and dissections associated with mild systemic features of Marfan syndrome. Nat Genet
44: 916–921.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4033668</ArticleId>
            <ArticleId IdType="pubmed">22772371</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Border WA, Okuda S, Languino LR, Sporn MB, Ruoslahti E. 1990. 
Suppression of experimental glomerulonephritis by antiserum against transforming growth factor β1. Nature
346: 371–374.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2374609</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brown MA, Zhao Q, Baker KA, Naik C, Chen C, Pukac L, Singh M, Tsareva T, Parice Y, Mahoney A, et al.
2005. 
Crystal structure of BMP-9 and functional interactions with pro-region and receptors. J Biol Chem
280: 25111–25118.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15851468</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bruna A, Darken RS, Rojo F, Ocana A, Penuelas S, Arias A, Paris R, Tortosa A, Mora J, Baselga J, et al.
2007. 
High TGFβ-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene. Cancer Cell
11: 147–160.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17292826</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brunkow ME, Jeffery EW, Hjerrild KA, Paeper B, Clark LB, Yasayko SA, Wilkinson JE, Galas D, Ziegler SF, Ramsdell F. 2001. 
Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet
27: 68–73.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11138001</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Butler SJ, Dodd J. 2003. 
A role for BMP heterodimers in roof plate-mediated repulsion of commissural axons. Neuron
38: 389–401.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12741987</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Butz H, Racz K, Hunyady L, Patocs A. 2012. 
Crosstalk between TGF-β signaling and the microRNA machinery. Trends Pharmacol Sci
33: 382–393.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22613783</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Caja L, Kahata K, Moustakas A. 2012. 
Context-dependent action of transforming growth factor β family members on normal and cancer stem cells. Curr Pharm Des
18: 4072–4086.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22630079</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chang C, Hemmati-Brivanlou A. 1999. 
Xenopus GDF6, a new antagonist of noggin and a partner of BMPs. Development
126: 3347–3357.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10393114</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Charbonneau NL, Carlson EJ, Tufa S, Sengle G, Manalo EC, Carlberg VM, Ramirez F, Keene DR, Sakai LY. 2010. 
In vivo studies of mutant fibrillin-1 microfibrils. J Biol Chem
285: 24943–24955.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2915730</ArticleId>
            <ArticleId IdType="pubmed">20529844</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen C, Shen MM. 2004. 
Two modes by which Lefty proteins inhibit nodal signaling. Curr Biol
14: 618–624.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15062104</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, McGrady G, Wahl SM. 2003. 
Conversion of peripheral CD4+CD25− naive T cells to CD4+CD25+ regulatory T cells by TGF-β induction of transcription factor Foxp3. J Exp Med
198: 1875–1886.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2194145</ArticleId>
            <ArticleId IdType="pubmed">14676299</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen C, Ware SM, Sato A, Houston-Hawkins DE, Habas R, Matzuk MM, Shen MM, Brown CW. 2006. 
The Vg1-related protein Gdf3 acts in a Nodal signaling pathway in the pre-gastrulation mouse embryo. Development
133: 319–329.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16368929</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen X, Xu H, Yuan P, Fang F, Huss M, Vega VB, Wong E, Orlov YL, Zhang W, Jiang J, et al.
2008. 
Integration of external signaling pathways with the core transcriptional network in embryonic stem cells. Cell
133: 1106–1117.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18555785</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Coffey RJ Jr, Bascom CC, Sipes NJ, Graves-Deal R, Weissman BE, Moses HL. 1988. 
Selective inhibition of growth-related gene expression in murine keratinocytes by transforming growth factor β. Mol Cell Biol
8: 3088–3093.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC363535</ArticleId>
            <ArticleId IdType="pubmed">2463471</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dallas SL, Miyazono K, Skerry TM, Mundy GR, Bonewald LF. 1995. 
Dual role for the latent transforming growth factor-β binding protein in storage of latent TGF-β in the extracellular matrix and as a structural matrix protein. J Cell Biol
131: 539–549.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2199978</ArticleId>
            <ArticleId IdType="pubmed">7593177</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Daopin S, Piez KA, Ogawa Y, Davies DR. 1992. 
Crystal structure of transforming growth factor-β2: An unusual fold for the superfamily. Science
257: 369–373.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1631557</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Datto MB, Li Y, Panus JF, Howe DJ, Xiong Y, Wang XF. 1995a. 
Transforming growth factor β induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proc Natl Acad Sci
92: 5545–5549.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC41732</ArticleId>
            <ArticleId IdType="pubmed">7777546</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Datto MB, Yu Y, Wang XF. 1995b. 
Functional analysis of the transforming growth factor β responsive elements in the WAF1/Cip1/p21 promoter. J Biol Chem
270: 28623–28628.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7499379</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>David L, Mallet C, Mazerbourg S, Feige JJ, Bailly S. 2007. 
Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells. Blood
109: 1953–1961.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17068149</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>David L, Feige JJ, Bailly S. 2009. 
Emerging role of bone morphogenetic proteins in angiogenesis. Cytokine Growth Factor Rev
20: 203–212.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19502096</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Davis BN, Hilyard AC, Lagna G, Hata A. 2008. 
SMAD proteins control DROSHA-mediated microRNA maturation. Nature
454: 56–61.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2653422</ArticleId>
            <ArticleId IdType="pubmed">18548003</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Martin R, Haendler B, Hofer-Warbinek R, Gaugitsch H, Wrann M, Schlusener H, Seifert JM, Bodmer S, Fontana A, Hofer E. 1987. 
Complementary DNA for human glioblastoma-derived T cell suppressor factor, a novel member of the transforming growth factor-β gene family. EMBO J
6: 3673–3677.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC553836</ArticleId>
            <ArticleId IdType="pubmed">3322813</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Denis M. 1994. 
Neutralization of transforming growth factor-β1 in a mouse model of immune-induced lung fibrosis. Immunology
82: 584–590.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1414922</ArticleId>
            <ArticleId IdType="pubmed">7835921</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Derynck R, Jarrett JA, Chen EY, Eaton DH, Bell JR, Assoian RK, Roberts AB, Sporn MB, Goeddel DV. 1985. 
Human transforming growth factor-β complementary DNA sequence and expression in normal and transformed cells. Nature
316: 701–705.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3861940</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Derynck R, Lindquist PB, Lee A, Wen D, Tamm J, Graycar JL, Rhee L, Mason AJ, Miller DA, Coffey RJ, et al.
1988. 
A new type of transforming growth factor-β, TGF-β3. EMBO J
7: 3737–3743.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC454948</ArticleId>
            <ArticleId IdType="pubmed">3208746</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Desmouliere A, Geinoz A, Gabbiani F, Gabbiani G. 1993. 
Transforming growth factor-β1 induces α-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts. J Cell Biol
122: 103–111.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2119614</ArticleId>
            <ArticleId IdType="pubmed">8314838</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ding N, Yu RT, Subramaniam N, Sherman MH, Wilson C, Rao R, Leblanc M, Coulter S, He M, Scott C, et al.
2013. 
A vitamin D receptor/SMAD genomic circuit gates hepatic fibrotic response. Cell
153: 601–613.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3673534</ArticleId>
            <ArticleId IdType="pubmed">23622244</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Doyle AJ, Doyle JJ, Bessling SL, Maragh S, Lindsay ME, Schepers D, Gillis E, Mortier G, Homfray T, Sauls K, et al.
2012. 
Mutations in the TGF-β repressor SKI cause Shprintzen–Goldberg syndrome with aortic aneurysm. Nat Genet
44: 1249–1254.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3545695</ArticleId>
            <ArticleId IdType="pubmed">23023332</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Edwards DR, Murphy G, Reynolds JJ, Whitham SE, Docherty AJ, Angel P, Heath JK. 1987. 
Transforming growth factor β modulates the expression of collagenase and metalloproteinase inhibitor. EMBO J
6: 1899–1904.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC553574</ArticleId>
            <ArticleId IdType="pubmed">2820711</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Egerman MA, Cadena SM, Gilbert JA, Meyer A, Nelson HN, Swalley SE, Mallozzi C, Jacobi C, Jennings LL, Clay I, et al.
2015. 
GDF11 increases with age and inhibits skeletal muscle regeneration. Cell Metab
22: 164–174.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4497834</ArticleId>
            <ArticleId IdType="pubmed">26001423</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ehata S, Johansson E, Katayama R, Koike S, Watanabe A, Hoshino Y, Katsuno Y, Komuro A, Koinuma D, Kano MR, et al.
2011. 
Transforming growth factor-β decreases the cancer-initiating cell population within diffuse-type gastric carcinoma cells. Oncogene
30: 1693–1705.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21132002</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eimon PM, Harland RM. 1999. 
In Xenopus embryos, BMP heterodimers are not required for mesoderm induction, but BMP activity is necessary for dorsal/ventral patterning. Dev Biol
216: 29–40.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10588861</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eto Y, Tsuji T, Takezawa M, Takano S, Yokogawa Y, Shibai H. 1987. 
Purification and characterization of erythroid differentiation factor (EDF) isolated from human leukemia cell line THP-1. Biochem Biophys Res Commun
142: 1095–1103.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3470005</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fearon ER, Vogelstein B. 1990. 
A genetic model for colorectal tumorigenesis. Cell
61: 759–767.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2188735</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferguson MW, Duncan J, Bond J, Bush J, Durani P, So K, Taylor L, Chantrey J, Mason T, James G, et al.
2009. 
Prophylactic administration of avotermin for improvement of skin scarring: Three double-blind, placebo-controlled, phase I/II studies. Lancet
373: 1264–1274.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19362676</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Flanders KC, Sullivan CD, Fujii M, Sowers A, Anzano MA, Arabshahi A, Major C, Deng C, Russo A, Mitchell JB, et al.
2002. 
Mice lacking Smad3 are protected against cutaneous injury induced by ionizing radiation. Am J Pathol
160: 1057–1068.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1867194</ArticleId>
            <ArticleId IdType="pubmed">11891202</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Flavell RA, Sanjabi S, Wrzesinski SH, Licona-Limon P. 2010. 
The polarization of immune cells in the tumour environment by TGFβ. Nat Rev Immunol
10: 554–567.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3885992</ArticleId>
            <ArticleId IdType="pubmed">20616810</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Florini JR, Roberts AB, Ewton DZ, Falen SL, Flanders KC, Sporn MB. 1986. 
Transforming growth factor-β. A very potent inhibitor of myoblast differentiation, identical to the differentiation inhibitor secreted by Buffalo rat liver cells. J Biol Chem
261: 16509–16513.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3465726</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gaarenstroom T, Hill CS. 2014. 
TGF-β signaling to chromatin: How Smads regulate transcription during self-renewal and differentiation. Semin Cell Dev Biol
32: 107–118.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24503509</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gafni O, Weinberger L, Mansour AA, Manor YS, Chomsky E, Ben-Yosef D, Kalma Y, Viukov S, Maza I, Zviran A, et al.
2013. 
Derivation of novel human ground state naive pluripotent stem cells. Nature
504: 282–286.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24172903</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garraway LA, Lander ES. 2013. 
Lessons from the cancer genome. Cell
153: 17–37.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23540688</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ge G, Hopkins DR, Ho WB, Greenspan DS. 2005. 
GDF11 forms a bone morphogenetic protein 1–activated latent complex that can modulate nerve growth factor-induced differentiation of PC12 cells. Mol Cell Biol
25: 5846–5858.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1168807</ArticleId>
            <ArticleId IdType="pubmed">15988002</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>George J, Roulot D, Koteliansky VE, Bissell DM. 1999. 
In vivo inhibition of rat stellate cell activation by soluble transforming growth factor β type II receptor: A potential new therapy for hepatic fibrosis. Proc Natl Acad Sci
96: 12719–12724.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC23066</ArticleId>
            <ArticleId IdType="pubmed">10535989</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gomis RR, Alarcon C, He W, Wang Q, Seoane J, Lash A, Massagué J. 2006a. 
A FoxO-Smad synexpression group in human keratinocytes. Proc Natl Acad Sci
103: 12747–12752.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1568919</ArticleId>
            <ArticleId IdType="pubmed">16908841</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gomis RR, Alarcon C, Nadal C, Van Poznak C, Massagué J. 2006b. 
C/EBPβ at the core of the TGFβ cytostatic response and its evasion in metastatic breast cancer cells. Cancer Cell
10: 203–214.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16959612</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goumans MJ, Valdimarsdottir G, Itoh S, Rosendahl A, Sideras P, ten Dijke P. 2002. 
Balancing the activation state of the endothelium via two distinct TGF-β type I receptors. EMBO J
21: 1743–1753.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC125949</ArticleId>
            <ArticleId IdType="pubmed">11927558</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, Vadas MA, Khew-Goodall Y, Goodall GJ. 2008. 
The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol
10: 593–601.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18376396</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grobet L, Martin LJ, Poncelet D, Pirottin D, Brouwers B, Riquet J, Schoeberlein A, Dunner S, Menissier F, Massabanda J, et al.
1997. 
A deletion in the bovine myostatin gene causes the double-muscled phenotype in cattle. Nat Genet
17: 71–74.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9288100</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hahn SA, Schutte M, Hoque AT, Moskaluk CA, da Costa LT, Rozenblum E, Weinstein CL, Fischer A, Yeo CJ, Hruban RH, et al.
1996. 
DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science
271: 350–353.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8553070</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hannon GJ, Beach D. 1994. 
p15INK4B is a potential effector of TGF-β-induced cell cycle arrest. Nature
371: 257–261.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8078588</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hassani SN, Totonchi M, Farrokhi A, Taei A, Larijani MR, Gourabi H, Baharvand H. 2012. 
Simultaneous suppression of TGF-β and ERK signaling contributes to the highly efficient and reproducible generation of mouse embryonic stem cells from previously considered refractory and non-permissive strains. Stem Cell Rev
8: 472–481.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21814763</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hata A, Lieberman J. 2015. 
Dysregulation of microRNA biogenesis and gene silencing in cancer. Sci Signal
8: re3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25783160</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hemmati-Brivanlou A, Kelly OG, Melton DA. 1994. 
Follistatin, an antagonist of activin, is expressed in the Spemann organizer and displays direct neuralizing activity. Cell
77: 283–295.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8168135</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Horiguchi M, Ota M, Rifkin DB. 2012. 
Matrix control of transforming growth factor-β function. J Biochem
152: 321–329.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3529568</ArticleId>
            <ArticleId IdType="pubmed">22923731</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hoshino Y, Nishida J, Katsuno Y, Koinuma D, Aoki T, Kokudo N, Miyazono K, Ehata S. 2015. 
Smad4 decreases the population of pancreatic cancer-initiating cells through transcriptional repression of ALDH1A1. Am J Pathol
185: 1457–1470.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25769430</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Iavarone A, Massagué J. 1997. 
Repression of the CDK activator Cdc25A and cell-cycle arrest by cytokine TGF-β in cells lacking the CDK inhibitor p15. Nature
387: 417–422.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9163429</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ignotz RA, Massagué J. 1985. 
Type β transforming growth factor controls the adipogenic differentiation of 3T3 fibroblasts. Proc Natl Acad Sci
82: 8530–8534.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC390950</ArticleId>
            <ArticleId IdType="pubmed">3001708</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ignotz RA, Massagué J. 1986. 
Transforming growth factor β stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. J Biol Chem
261: 4337–4345.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3456347</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ikushima H, Miyazono K. 2010. 
TGFβ signalling: A complex web in cancer progression. Nat Rev Cancer
10: 415–424.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20495575</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ikushima H, Todo T, Ino Y, Takahashi M, Miyazawa K, Miyazono K. 2009. 
Autocrine TGF-β signaling maintains tumorigenicity of glioma-initiating cells through Sry-related HMG-box factors. Cell Stem Cell
5: 504–514.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19896441</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Imbeaud S, Faure E, Lamarre I, Mattei MG, di Clemente N, Tizard R, Carre-Eusebe D, Belville C, Tragethon L, Tonkin C, et al.
1995. 
Insensitivity to anti-Müllerian hormone due to a mutation in the human anti-Müllerian hormone receptor. Nat Genet
11: 382–388.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7493017</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Isogai Z, Ono RN, Ushiro S, Keene DR, Chen Y, Mazzieri R, Charbonneau NL, Reinhardt DP, Rifkin DB, Sakai LY. 2003. 
Latent transforming growth factor β-binding protein 1 interacts with fibrillin and is a microfibril-associated protein. J Biol Chem
278: 2750–2757.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12429738</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Israel DI, Nove J, Kerns KM, Kaufman RJ, Rosen V, Cox KA, Wozney JM. 1996. 
Heterodimeric bone morphogenetic proteins show enhanced activity in vitro and in vivo. Growth Factors
13: 291–300.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8919035</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Iwano M, Plieth D, Danoff TM, Xue C, Okada H, Neilson EG. 2002. 
Evidence that fibroblasts derive from epithelium during tissue fibrosis. J Clin Invest
110: 341–350.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC151091</ArticleId>
            <ArticleId IdType="pubmed">12163453</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>James D, Levine AJ, Besser D, Hemmati-Brivanlou A. 2005. 
TGFβ/activin/nodal signaling is necessary for the maintenance of pluripotency in human embryonic stem cells. Development
132: 1273–1282.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15703277</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jamin SP, Arango NA, Mishina Y, Hanks MC, Behringer RR. 2002. 
Requirement of Bmpr1a for Müllerian duct regression during male sexual development. Nat Genet
32: 408–410.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12368913</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Janssens K, Gershoni-Baruch R, Guanabens N, Migone N, Ralston S, Bonduelle M, Lissens W, Van Maldergem L, Vanhoenacker F, Verbruggen L, et al.
2000. 
Mutations in the gene encoding the latency-associated peptide of TGF-β1 cause Camurati–Engelmann disease. Nat Genet
26: 273–275.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11062463</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jian H, Shen X, Liu I, Semenov M, He X, Wang XF. 2006. 
Smad3-dependent nuclear translocation of β-catenin is required for TGF-β1-induced proliferation of bone marrow-derived adult human mesenchymal stem cells. Genes Dev
20: 666–674.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1413283</ArticleId>
            <ArticleId IdType="pubmed">16543220</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Judge DP, Biery NJ, Keene DR, Geubtner J, Myers L, Huso DL, Sakai LY, Dietz HC. 2004. 
Evidence for a critical contribution of haploinsufficiency in the complex pathogenesis of Marfan syndrome. J Clin Invest
114: 172–181.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC449744</ArticleId>
            <ArticleId IdType="pubmed">15254584</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaartinen V, Voncken JW, Shuler C, Warburton D, Bu D, Heisterkamp N, Groffen J. 1995. 
Abnormal lung development and cleft palate in mice lacking TGF-β3 indicates defects of epithelial-mesenchymal interaction. Nat Genet
11: 415–421.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7493022</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kalluri R, Weinberg RA. 2009. 
The basics of epithelial-mesenchymal transition. J Clin Invest
119: 1420–1428.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2689101</ArticleId>
            <ArticleId IdType="pubmed">19487818</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kambadur R, Sharma M, Smith TP, Bass JJ. 1997. 
Mutations in myostatin (GDF8) in double-muscled Belgian Blue and Piedmontese cattle. Genome Res
7: 910–916.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9314496</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kane CJ, Hebda PA, Mansbridge JN, Hanawalt PC. 1991. 
Direct evidence for spatial and temporal regulation of transforming growth factor β1 expression during cutaneous wound healing. J Cell Physiol
148: 157–173.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1907288</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kang Y, Chen CR, Massagué J. 2003. 
A self-enabling TGFβ response coupled to stress signaling: Smad engages stress response factor ATF3 for Id1 repression in epithelial cells. Mol Cell
11: 915–926.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12718878</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Katsuno Y, Lamouille S, Derynck R. 2013. 
TGF-β signaling and epithelial-mesenchymal transition in cancer progression. Curr Opin Oncol
25: 76–84.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23197193</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kawabata M, Inoue H, Hanyu A, Imamura T, Miyazono K. 1998. 
Smad proteins exist as monomers in vivo and undergo homo- and hetero-oligomerization upon activation by serine/threonine kinase receptors. EMBO J
17: 4056–4065.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1170738</ArticleId>
            <ArticleId IdType="pubmed">9670020</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kehrl JH, Wakefield LM, Roberts AB, Jakowlew S, Alvarez-Mon M, Derynck R, Sporn MB, Fauci AS. 1986. 
Production of transforming growth factor β by human T lymphocytes and its potential role in the regulation of T cell growth. J Exp Med
163: 1037–1050.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2188095</ArticleId>
            <ArticleId IdType="pubmed">2871125</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim KK, Kugler MC, Wolters PJ, Robillard L, Galvez MG, Brumwell AN, Sheppard D, Chapman HA. 2006. 
Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix. Proc Natl Acad Sci
103: 13180–13185.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1551904</ArticleId>
            <ArticleId IdType="pubmed">16924102</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kimchi A, Wang XF, Weinberg RA, Cheifetz S, Massagué J. 1988. 
Absence of TGF-β receptors and growth inhibitory responses in retinoblastoma cells. Science
240: 196–199.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2895499</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kimelman D, Kirschner M. 1987. 
Synergistic induction of mesoderm by FGF and TGF-β and the identification of an mRNA coding for FGF in the early Xenopus embryo. Cell
51: 869–877.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3479265</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kinoshita A, Saito T, Tomita H, Makita Y, Yoshida K, Ghadami M, Yamada K, Kondo S, Ikegawa S, Nishimura G, et al.
2000. 
Domain-specific mutations in TGFB1 result in Camurati-Engelmann disease. Nat Genet
26: 19–20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10973241</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koinuma D, Tsutsumi S, Kamimura N, Imamura T, Aburatani H, Miyazono K. 2009a. 
Promoter-wide analysis of Smad4 binding sites in human epithelial cells. Cancer Sci
100: 2133–2142.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19686287</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koinuma D, Tsutsumi S, Kamimura N, Taniguchi H, Miyazawa K, Sunamura M, Imamura T, Miyazono K, Aburatani H. 2009b. 
Chromatin immunoprecipitation on microarray analysis of Smad2/3 binding sites reveals roles of ETS1 and TFAP2A in transforming growth factor β signaling. Mol Cell Biol
29: 172–186.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2612478</ArticleId>
            <ArticleId IdType="pubmed">18955504</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Korn T, Bettelli E, Gao W, Awasthi A, Jager A, Strom TB, Oukka M, Kuchroo VK. 2007. 
IL-21 initiates an alternative pathway to induce proinflammatory TH17 cells. Nature
448: 484–487.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3805028</ArticleId>
            <ArticleId IdType="pubmed">17581588</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Krieglstein K, Zheng F, Unsicker K, Alzheimer C. 2011. 
More than being protective: Functional roles for TGF-β/activin signaling pathways at central synapses. Trends Neurosci
34: 421–429.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21742388</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuwahara F, Kai H, Tokuda K, Kai M, Takeshita A, Egashira K, Imaizumi T. 2002. 
Transforming growth factor-β function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats. Circulation
106: 130–135.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12093782</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Labelle M, Begum S, Hynes RO. 2011. 
Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell
20: 576–590.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3487108</ArticleId>
            <ArticleId IdType="pubmed">22094253</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lagna G, Hata A, Hemmati-Brivanlou A, Massagué J. 1996. 
Partnership between DPC4 and SMAD proteins in TGF-β signalling pathways. Nature
383: 832–836.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8893010</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee SJ, McPherron AC. 2001. 
Regulation of myostatin activity and muscle growth. Proc Natl Acad Sci
98: 9306–9311.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC55416</ArticleId>
            <ArticleId IdType="pubmed">11459935</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee KL, Lim SK, Orlov YL, Yit le Y, Yang H, Ang LT, Poellinger L, Lim B. 2011. 
Graded Nodal/Activin signaling titrates conversion of quantitative phospho-Smad2 levels into qualitative embryonic stem cell fate decisions. PLoS Genet
7: e1002130.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3121749</ArticleId>
            <ArticleId IdType="pubmed">21731500</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leof EB, Proper JA, Goustin AS, Shipley GD, DiCorleto PE, Moses HL. 1986. 
Induction of c-sis mRNA and activity similar to platelet-derived growth factor by transforming growth factor β: A proposed model for indirect mitogenesis involving autocrine activity. Proc Natl Acad Sci
83: 2453–2457.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC323316</ArticleId>
            <ArticleId IdType="pubmed">3010310</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Levine AJ, Brivanlou AH. 2006. 
GDF3, a BMP inhibitor, regulates cell fate in stem cells and early embryos. Development
133: 209–216.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16339188</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Levine AJ, Levine ZJ, Brivanlou AH. 2009. 
GDF3 is a BMP inhibitor that can activate Nodal signaling only at very high doses. Dev Biol
325: 43–48.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3740937</ArticleId>
            <ArticleId IdType="pubmed">18823971</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li MO, Flavell RA. 2008. 
TGF-β: A master of all T cell trades. Cell
134: 392–404.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3677783</ArticleId>
            <ArticleId IdType="pubmed">18692464</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lindsay ME, Dietz HC. 2011. 
Lessons on the pathogenesis of aneurysm from heritable conditions. Nature
473: 308–316.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3622871</ArticleId>
            <ArticleId IdType="pubmed">21593863</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lindsay ME, Schepers D, Bolar NA, Doyle JJ, Gallo E, Fert-Bober J, Kempers MJ, Fishman EK, Chen Y, Myers L, et al.
2012. 
Loss-of-function mutations in TGFB2 cause a syndromic presentation of thoracic aortic aneurysm. Nat Genet
44: 922–927.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3616632</ArticleId>
            <ArticleId IdType="pubmed">22772368</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Little SC, Mullins MC. 2009. 
Bone morphogenetic protein heterodimers assemble heteromeric type I receptor complexes to pattern the dorsoventral axis. Nat Cell Biol
11: 637–643.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2757091</ArticleId>
            <ArticleId IdType="pubmed">19377468</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Y, Zhang P, Li J, Kulkarni AB, Perruche S, Chen W. 2008. 
A critical function for TGF-β signaling in the development of natural CD4+CD25+Foxp3+ regulatory T cells. Nat Immunol
9: 632–640.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18438410</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Loeys BL, Chen J, Neptune ER, Judge DP, Podowski M, Holm T, Meyers J, Leitch CC, Katsanis N, Sharifi N, et al.
2005. 
A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. Nat Genet
37: 275–281.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15731757</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Loeys BL, Schwarze U, Holm T, Callewaert BL, Thomas GH, Pannu H, De Backer JF, Oswald GL, Symoens S, Manouvrier S, et al.
2006. 
Aneurysm syndromes caused by mutations in the TGF-β receptor. N Engl J Med
355: 788–798.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16928994</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Loffredo FS, Steinhauser ML, Jay SM, Gannon J, Pancoast JR, Yalamanchi P, Sinha M, Dall’Osso C, Khong D, Shadrach JL, et al.
2013. 
Growth differentiation factor 11 is a circulating factor that reverses age-related cardiac hypertrophy. Cell
153: 828–839.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3677132</ArticleId>
            <ArticleId IdType="pubmed">23663781</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lonardo E, Hermann PC, Mueller MT, Huber S, Balic A, Miranda-Lorenzo I, Zagorac S, Alcala S, Rodriguez-Arabaolaza I, Ramirez JC, et al.
2011. 
Nodal/Activin signaling drives self-renewal and tumorigenicity of pancreatic cancer stem cells and provides a target for combined drug therapy. Cell Stem Cell
9: 433–446.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22056140</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lund LR, Riccio A, Andreasen PA, Nielsen LS, Kristensen P, Laiho M, Saksela O, Blasi F, Dano K. 1987. 
Transforming growth factor-β is a strong and fast acting positive regulator of the level of type-1 plasminogen activator inhibitor mRNA in WI-38 human lung fibroblasts. EMBO J
6: 1281–1286.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC553930</ArticleId>
            <ArticleId IdType="pubmed">3111844</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maeda S, Hayashi M, Komiya S, Imamura T, Miyazono K. 2004. 
Endogenous TGF-β signaling suppresses maturation of osteoblastic mesenchymal cells. EMBO J
23: 552–563.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1271802</ArticleId>
            <ArticleId IdType="pubmed">14749725</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, et al.
2008. 
The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell
133: 704–715.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2728032</ArticleId>
            <ArticleId IdType="pubmed">18485877</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J, Fan RS, Zborowska E, Kinzler KW, Vogelstein B, et al.
1995. 
Inactivation of the type II TGF-β receptor in colon cancer cells with microsatellite instability. Science
268: 1336–1338.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7761852</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Massagué J, Cheifetz S, Endo T, Nadal-Ginard B. 1986. 
Type β transforming growth factor is an inhibitor of myogenic differentiation. Proc Natl Acad Sci
83: 8206–8210.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC386896</ArticleId>
            <ArticleId IdType="pubmed">3022285</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mathews LS, Vale WW. 1991. 
Expression cloning of an activin receptor, a predicted transmembrane serine kinase. Cell
65: 973–982.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1646080</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matsuyama S, Iwadate M, Kondo M, Saitoh M, Hanyu A, Shimizu K, Aburatani H, Mishima HK, Imamura T, Miyazono K, et al.
2003. 
SB-431542 and Gleevec inhibit transforming growth factor-β-induced proliferation of human osteosarcoma cells. Cancer Res
63: 7791–7798.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14633705</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mazerbourg S, Klein C, Roh J, Kaivo-Oja N, Mottershead DG, Korchynskyi O, Ritvos O, Hsueh AJ. 2004. 
Growth differentiation factor-9 signaling is mediated by the type I receptor, activin receptor-like kinase 5. Mol Endocrinol
18: 653–665.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14684852</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McPherron AC, Lee SJ. 1997. 
Double muscling in cattle due to mutations in the myostatin gene. Proc Natl Acad Sci
94: 12457–12461.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC24998</ArticleId>
            <ArticleId IdType="pubmed">9356471</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McPherron AC, Lawler AM, Lee SJ. 1997. 
Regulation of skeletal muscle mass in mice by a new TGF-β superfamily member. Nature
387: 83–90.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9139826</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meynard D, Kautz L, Darnaud V, Canonne-Hergaux F, Coppin H, Roth MP. 2009. 
Lack of the bone morphogenetic protein BMP6 induces massive iron overload. Nat Genet
41: 478–481.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19252488</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mi LZ, Brown CT, Gao Y, Tian Y, Le VQ, Walz T, Springer TA. 2015. 
Structure of bone morphogenetic protein 9 procomplex. Proc Natl Acad Sci
112: 3710–3715.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4378411</ArticleId>
            <ArticleId IdType="pubmed">25751889</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mizuguchi T, Collod-Beroud G, Akiyama T, Abifadel M, Harada N, Morisaki T, Allard D, Varret M, Claustres M, Morisaki H, et al.
2004. 
Heterozygous TGFBR2 mutations in Marfan syndrome. Nat Genet
36: 855–860.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2230615</ArticleId>
            <ArticleId IdType="pubmed">15235604</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moore RK, Otsuka F, Shimasaki S. 2003. 
Molecular basis of bone morphogenetic protein-15 signaling in granulosa cells. J Biol Chem
278: 304–310.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12419820</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morikawa M, Koinuma D, Tsutsumi S, Vasilaki E, Kanki Y, Heldin CH, Aburatani H, Miyazono K. 2011. 
ChIP-seq reveals cell type-specific binding patterns of BMP-specific Smads and a novel binding motif. Nucleic Acids Res
39: 8712–8727.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3203580</ArticleId>
            <ArticleId IdType="pubmed">21764776</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morikawa M, Koinuma D, Miyazono K, Heldin CH. 2013. 
Genome-wide mechanisms of Smad binding. Oncogene
32: 1609–1615.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3615190</ArticleId>
            <ArticleId IdType="pubmed">22614010</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morinaga C, Saito D, Nakamura S, Sasaki T, Asakawa S, Shimizu N, Mitani H, Furutani-Seiki M, Tanaka M, Kondoh H. 2007. 
The hotei mutation of medaka in the anti-Müllerian hormone receptor causes the dysregulation of germ cell and sexual development. Proc Natl Acad Sci
104: 9691–9696.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1887600</ArticleId>
            <ArticleId IdType="pubmed">17535919</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mullen AC, Orlando DA, Newman JJ, Loven J, Kumar RM, Bilodeau S, Reddy J, Guenther MG, DeKoter RP, Young RA. 2011. 
Master transcription factors determine cell-type-specific responses to TGF-β signaling. Cell
147: 565–576.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3212730</ArticleId>
            <ArticleId IdType="pubmed">22036565</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Munger JS, Huang X, Kawakatsu H, Griffiths MJ, Dalton SL, Wu J, Pittet JF, Kaminski N, Garat C, Matthay MA, et al.
1999. 
The integrin αvβ6 binds and activates latent TGFβ1: A mechanism for regulating pulmonary inflammation and fibrosis. Cell
96: 319–328.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10025398</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mustoe TA, Pierce GF, Thomason A, Gramates P, Sporn MB, Deuel TF. 1987. 
Accelerated healing of incisional wounds in rats induced by transforming growth factor-β. Science
237: 1333–1336.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2442813</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Naka K, Hoshii T, Muraguchi T, Tadokoro Y, Ooshio T, Kondo Y, Nakao S, Motoyama N, Hirao A. 2010. 
TGF-β-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia. Nature
463: 676–680.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20130650</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nakao A, Afrakhte M, Moren A, Nakayama T, Christian JL, Heuchel R, Itoh S, Kawabata M, Heldin NE, Heldin CH, et al.
1997. 
Identification of Smad7, a TGFβ-inducible antagonist of TGF-β signalling. Nature
389: 631–635.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9335507</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nakao A, Fujii M, Matsumura R, Kumano K, Saito Y, Miyazono K, Iwamoto I. 1999. 
Transient gene transfer and expression of Smad7 prevents bleomycin-induced lung fibrosis in mice. J Clin Invest
104: 5–11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC408403</ArticleId>
            <ArticleId IdType="pubmed">10393693</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Neptune ER, Frischmeyer PA, Arking DE, Myers L, Bunton TE, Gayraud B, Ramirez F, Sakai LY, Dietz HC. 2003. 
Dysregulation of TGF-β activation contributes to pathogenesis in Marfan syndrome. Nat Genet
33: 407–411.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12598898</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ng F, Boucher S, Koh S, Sastry KS, Chase L, Lakshmipathy U, Choong C, Yang Z, Vemuri MC, Rao MS, et al.
2008. 
PDGF, TGF-β, and FGF signaling is important for differentiation and growth of mesenchymal stem cells (MSCs): Transcriptional profiling can identify markers and signaling pathways important in differentiation of MSCs into adipogenic, chondrogenic, and osteogenic lineages. Blood
112: 295–307.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18332228</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Niehrs C, Pollet N. 1999. 
Synexpression groups in eukaryotes. Nature
402: 483–487.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10591207</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ogawa K, Saito A, Matsui H, Suzuki H, Ohtsuka S, Shimosato D, Morishita Y, Watabe T, Niwa H, Miyazono K. 2007. 
Activin-nodal signaling is involved in propagation of mouse embryonic stem cells. J Cell Sci
120: 55–65.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17182901</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oh SP, Yeo CY, Lee Y, Schrewe H, Whitman M, Li E. 2002. 
Activin type IIA and IIB receptors mediate Gdf11 signaling in axial vertebral patterning. Genes Dev
16: 2749–2754.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC187472</ArticleId>
            <ArticleId IdType="pubmed">12414726</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ohta M, Greenberger JS, Anklesaria P, Bassols A, Massagué J. 1987. 
Two forms of transforming growth factor-β distinguished by multipotential haematopoietic progenitor cells. Nature
329: 539–541.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2889143</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oshimori N, Fuchs E. 2012. 
The harmonies played by TGF-β in stem cell biology. Cell Stem Cell
11: 751–764.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3612991</ArticleId>
            <ArticleId IdType="pubmed">23217421</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Palumbo-Zerr K, Zerr P, Distler A, Fliehr J, Mancuso R, Huang J, Mielenz D, Tomcik M, Furnrohr BG, Scholtysek C, et al.
2015. 
Orphan nuclear receptor NR4A1 regulates transforming growth factor-β signaling and fibrosis. Nat Med
21: 150–158.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25581517</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pardali E, Goumans MJ, ten Dijke P. 2010. 
Signaling by members of the TGF-β family in vascular morphogenesis and disease. Trends Cell Biol
20: 556–567.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20656490</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park SM, Gaur AB, Lengyel E, Peter ME. 2008. 
The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev
22: 894–907.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2279201</ArticleId>
            <ArticleId IdType="pubmed">18381893</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peng J, Li Q, Wigglesworth K, Rangarajan A, Kattamuri C, Peterson RT, Eppig JJ, Thompson TB, Matzuk MM. 2013. 
Growth differentiation factor 9:bone morphogenetic protein 15 heterodimers are potent regulators of ovarian functions. Proc Natl Acad Sci
10: E776–E785.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3581982</ArticleId>
            <ArticleId IdType="pubmed">23382188</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Penuelas S, Anido J, Prieto-Sanchez RM, Folch G, Barba I, Cuartas I, Garcia-Dorado D, Poca MA, Sahuquillo J, Baselga J, et al.
2009. 
TGF-β increases glioma-initiating cell self-renewal through the induction of LIF in human glioblastoma. Cancer Cell
15: 315–327.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19345330</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pickup M, Novitskiy S, Moses HL. 2013. 
The roles of TGFβ in the tumour microenvironment. Nat Rev Cancer
13: 788–799.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4025940</ArticleId>
            <ArticleId IdType="pubmed">24132110</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pietenpol JA, Stein RW, Moran E, Yaciuk P, Schlegel R, Lyons RM, Pittelkow MR, Munger K, Howley PM, Moses HL. 1990. 
TGF-β1 inhibition of c-myc transcription and growth in keratinocytes is abrogated by viral transforming proteins with pRB binding domains. Cell
61: 777–785.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2140528</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Polyak K, Kato JY, Solomon MJ, Sherr CJ, Massagué J, Roberts JM, Koff A. 1994. 
p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-β and contact inhibition to cell cycle arrest. Genes Dev
8: 9–22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8288131</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Postlethwaite AE, Keski-Oja J, Moses HL, Kang AH. 1987. 
Stimulation of the chemotactic migration of human fibroblasts by transforming growth factor β. J Exp Med
165: 251–256.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2188256</ArticleId>
            <ArticleId IdType="pubmed">3491869</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qin H, Chan MW, Liyanarachchi S, Balch C, Potter D, Souriraj IJ, Cheng AS, Agosto-Perez FJ, Nikonova EV, Yan PS, et al.
2009. 
An integrative ChIP-chip and gene expression profiling to model SMAD regulatory modules. BMC Syst Biol
3: 73.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2724489</ArticleId>
            <ArticleId IdType="pubmed">19615063</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Raftery LA, Twombly V, Wharton K, Gelbart WM. 1995. 
Genetic screens to identify elements of the decapentaplegic signaling pathway in Drosophila. Genetics
139: 241–254.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1206322</ArticleId>
            <ArticleId IdType="pubmed">7705627</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ristow HJ. 1986. 
BSC-1 growth inhibitor/type β transforming growth factor is a strong inhibitor of thymocyte proliferation. Proc Natl Acad Sci
83: 5531–5533.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC386321</ArticleId>
            <ArticleId IdType="pubmed">3488549</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roberts AB, Lamb LC, Newton DL, Sporn MB, De Larco JE, Todaro GJ. 1980. 
Transforming growth factors: Isolation of polypeptides from virally and chemically transformed cells by acid/ethanol extraction. Proc Natl Acad Sci
77: 3494–3498.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC349643</ArticleId>
            <ArticleId IdType="pubmed">6251462</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roberts AB, Anzano MA, Lamb LC, Smith JM, Sporn MB. 1981. 
New class of transforming growth factors potentiated by epidermal growth factor: Isolation from non-neoplastic tissues. Proc Natl Acad Sci
78: 5339–5343.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC348740</ArticleId>
            <ArticleId IdType="pubmed">6975480</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roberts AB, Anzano MA, Meyers CA, Wideman J, Blacher R, Pan YC, Stein S, Lehrman SR, Smith JM, Lamb LC, et al.
1983. 
Purification and properties of a type β transforming growth factor from bovine kidney. Biochemistry
22: 5692–5698.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6607069</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roberts AB, Anzano MA, Wakefield LM, Roche NS, Stern DF, Sporn MB. 1985. 
Type β transforming growth factor: A bifunctional regulator of cellular growth. Proc Natl Acad Sci
82: 119–123.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC396983</ArticleId>
            <ArticleId IdType="pubmed">3871521</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roberts AB, Sporn MB, Assoian RK, Smith JM, Roche NS, Wakefield LM, Heine UI, Liotta LA, Falanga V, Kehrl JH, et al.
1986. 
Transforming growth factor type β: Rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci
83: 4167–4171.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC323692</ArticleId>
            <ArticleId IdType="pubmed">2424019</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rosa F, Roberts AB, Danielpour D, Dart LL, Sporn MB, Dawid IB. 1988. 
Mesoderm induction in amphibians: The role of TGF-β2-like factors. Science
239: 783–785.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3422517</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Russell WE, Coffey RJ Jr, Ouellette AJ, Moses HL. 1988. 
Type β transforming growth factor reversibly inhibits the early proliferative response to partial hepatectomy in the rat. Proc Natl Acad Sci
85: 5126–5130.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC281701</ArticleId>
            <ArticleId IdType="pubmed">3164865</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saito T, Kinoshita A, Yoshiura K, Makita Y, Wakui K, Honke K, Niikawa N, Taniguchi N. 2001. 
Domain-specific mutations of a transforming growth factor (TGF)-β1 latency-associated peptide cause Camurati–Engelmann disease because of the formation of a constitutively active form of TGF-β1. J Biol Chem
276: 11469–11472.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11278244</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sakaki-Yumoto M, Katsuno Y, Derynck R. 2013. 
TGF-β family signaling in stem cells. Biochim Biophys Acta
1830: 2280–2296.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4240309</ArticleId>
            <ArticleId IdType="pubmed">22959078</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sanford LP, Ormsby I, Gittenberger-de Groot AC, Sariola H, Friedman R, Boivin GP, Cardell EL, Doetschman T. 1997. 
TGFβ2 knockout mice have multiple developmental defects that are non-overlapping with other TGFβ knockout phenotypes. Development
124: 2659–2670.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3850286</ArticleId>
            <ArticleId IdType="pubmed">9217007</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sartori R, Schirwis E, Blaauw B, Bortolanza S, Zhao J, Enzo E, Stantzou A, Mouisel E, Toniolo L, Ferry A, et al.
2013. 
BMP signaling controls muscle mass. Nat Genet
45: 1309–1318.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24076600</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sato M, Muragaki Y, Saika S, Roberts AB, Ooshima A. 2003. 
Targeted disruption of TGF-β1/Smad3 signaling protects against renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction. J Clin Invest
112: 1486–1494.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC259132</ArticleId>
            <ArticleId IdType="pubmed">14617750</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Savage C, Das P, Finelli AL, Townsend SR, Sun CY, Baird SE, Padgett RW. 1996. 
Caenorhabditis elegans genes sma-2, sma-3, and sma-4 define a conserved family of transforming growth factor β pathway components. Proc Natl Acad Sci
93: 790–794.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC40134</ArticleId>
            <ArticleId IdType="pubmed">8570636</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schlunegger MP, Grütter MG. 1992. 
An unusual feature revealed by the crystal structure at 2.2 Å resolution of human transforming growth factor-β2. Nature
358: 430–434.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1641027</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schubert D, Kimura H, LaCorbiere M, Vaughan J, Karr D, Fischer WH. 1990. 
Activin is a nerve cell survival molecule. Nature
344: 868–870.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2330043</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sekelsky JJ, Newfeld SJ, Raftery LA, Chartoff EH, Gelbart WM. 1995. 
Genetic characterization and cloning of mothers against dpp, a gene required for decapentaplegic function in Drosophila melanogaster. Genetics
139: 1347–1358.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1206461</ArticleId>
            <ArticleId IdType="pubmed">7768443</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sengle G, Charbonneau NL, Ono RN, Sasaki T, Alvarez J, Keene DR, Bachinger HP, Sakai LY. 2008. 
Targeting of bone morphogenetic protein growth factor complexes to fibrillin. J Biol Chem
283: 13874–13888.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2376219</ArticleId>
            <ArticleId IdType="pubmed">18339631</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seyedin SM, Thomas TC, Thompson AY, Rosen DM, Piez KA. 1985. 
Purification and characterization of two cartilage-inducing factors from bovine demineralized bone. Proc Natl Acad Sci
82: 2267–2271.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC397538</ArticleId>
            <ArticleId IdType="pubmed">3857579</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shah M, Foreman DM, Ferguson MW. 1995. 
Neutralisation of TGF-β1 and TGF-β2 or exogenous addition of TGF-β3 to cutaneous rat wounds reduces scarring. J Cell Sci
108: 985–1002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7542672</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shi M, Zhu J, Wang R, Chen X, Mi L, Walz T, Springer TA. 2011. 
Latent TGF-β structure and activation. Nature
474: 343–349.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4717672</ArticleId>
            <ArticleId IdType="pubmed">21677751</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shipley GD, Childs CB, Volkenant ME, Moses HL. 1984. 
Differential effects of epidermal growth factor, transforming growth factor, and insulin on DNA and protein synthesis and morphology in serum-free cultures of AKR-2B cells. Cancer Res
44: 710–716.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6362853</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shipley GD, Pittelkow MR, Wille JJ Jr, Scott RE, Moses HL. 1986. 
Reversible inhibition of normal human prokeratinocyte proliferation by type β transforming growth factor-growth inhibitor in serum-free medium. Cancer Res
46: 2068–2071.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2418960</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shirakihara T, Horiguchi K, Miyazawa K, Ehata S, Shibata T, Morita I, Miyazono K, Saitoh M. 2011. 
TGF-β regulates isoform switching of FGF receptors and epithelial-mesenchymal transition. EMBO J
30: 783–795.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3041949</ArticleId>
            <ArticleId IdType="pubmed">21224849</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shull MM, Ormsby I, Kier AB, Pawlowski S, Diebold RJ, Yin M, Allen R, Sidman C, Proetzel G, Calvin D, et al.
1992. 
Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory disease. Nature
359: 693–699.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3889166</ArticleId>
            <ArticleId IdType="pubmed">1436033</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Siegel PM, Massagué J. 2003. 
Cytostatic and apoptotic actions of TGF-β in homeostasis and cancer. Nat Rev Cancer
3: 807–821.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14557817</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Siegel PM, Massagué J. 2008. 
Growth control by TGF-β: Mechanisms controlling cell cycle progression and apoptosis. The TGF-β family (eds. Derynck R, Miyazono K), pp. 333–362. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.</Citation>
        </Reference>
        <Reference>
          <Citation>Sievers F, Wilm A, Dineen D, Gibson TJ, Karplus K, Li W, Lopez R, McWilliam H, Remmert M, Soding J, et al.
2011. 
Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. Mol Syst Biol
7: 539.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3261699</ArticleId>
            <ArticleId IdType="pubmed">21988835</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Silberstein GB, Daniel CW. 1987. 
Reversible inhibition of mammary gland growth by transforming growth factor-β. Science
237: 291–293.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3474783</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sime PJ, Xing Z, Graham FL, Csaky KG, Gauldie J. 1997. 
Adenovector-mediated gene transfer of active transforming growth factor-β1 induces prolonged severe fibrosis in rat lung. J Clin Invest
100: 768–776.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC508247</ArticleId>
            <ArticleId IdType="pubmed">9259574</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sinha M, Jang YC, Oh J, Khong D, Wu EY, Manohar R, Miller C, Regalado SG, Loffredo FS, Pancoast JR, et al.
2014. 
Restoring systemic GDF11 levels reverses age-related dysfunction in mouse skeletal muscle. Science
344: 649–652.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4104429</ArticleId>
            <ArticleId IdType="pubmed">24797481</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smith WC, Harland RM. 1992. 
Expression cloning of noggin, a new dorsalizing factor localized to the Spemann organizer in Xenopus embryos. Cell
70: 829–840.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1339313</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sporn MB, Roberts AB, Shull JH, Smith JM, Ward JM, Sodek J. 1983. 
Polypeptide transforming growth factors isolated from bovine sources and used for wound healing in vivo. Science
219: 1329–1331.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6572416</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Suzuki A, Kaneko E, Maeda J, Ueno N. 1997. 
Mesoderm induction by BMP-4 and -7 heterodimers. Biochem Biophys Res Commun
232: 153–156.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9125121</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tabibzadeh S, Hemmati-Brivanlou A. 2006. 
Lefty at the crossroads of “stemness” and differentiative events. Stem Cells
24: 1998–2006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16728558</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Taipale J, Miyazono K, Heldin CH, Keski-Oja J. 1994. 
Latent transforming growth factor-β1 associates to fibroblast extracellular matrix via latent TGF-β binding protein. J Cell Biol
124: 171–181.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2119892</ArticleId>
            <ArticleId IdType="pubmed">8294500</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang B, Vu M, Booker T, Santner SJ, Miller FR, Anver MR, Wakefield LM. 2003. 
TGF-β switches from tumor suppressor to prometastatic factor in a model of breast cancer progression. J Clin Invest
112: 1116–1124.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC198530</ArticleId>
            <ArticleId IdType="pubmed">14523048</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang B, Yoo N, Vu M, Mamura M, Nam JS, Ooshima A, Du Z, Desprez PY, Anver MR, Michalowska AM, et al.
2007. 
Transforming growth factor-β can suppress tumorigenesis through effects on the putative cancer stem or early progenitor cell and committed progeny in a breast cancer xenograft model. Cancer Res
67: 8643–8652.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2427144</ArticleId>
            <ArticleId IdType="pubmed">17875704</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang Y, Wu X, Lei W, Pang L, Wan C, Shi Z, Zhao L, Nagy TR, Peng X, Hu J, et al.
2009. 
TGF-β1-induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nat Med
15: 757–765.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2727637</ArticleId>
            <ArticleId IdType="pubmed">19584867</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Theunissen TW, Powell BE, Wang H, Mitalipova M, Faddah DA, Reddy J, Fan ZP, Maetzel D, Ganz K, Shi L, et al.
2014. 
Systematic identification of culture conditions for induction and maintenance of naive human pluripotency. Cell Stem Cell
15: 471–487.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4184977</ArticleId>
            <ArticleId IdType="pubmed">25090446</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Trompouki E, Bowman TV, Lawton LN, Fan ZP, Wu DC, DiBiase A, Martin CS, Cech JN, Sessa AK, Leblanc JL, et al.
2011. 
Lineage regulators direct BMP and Wnt pathways to cell-specific programs during differentiation and regeneration. Cell
147: 577–589.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3219441</ArticleId>
            <ArticleId IdType="pubmed">22036566</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tucker RF, Shipley GD, Moses HL, Holley RW. 1984. 
Growth inhibitor from BSC-1 cells closely related to platelet type β transforming growth factor. Science
226: 705–707.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6093254</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vallier L, Alexander M, Pedersen RA. 2005. 
Activin/nodal and FGF pathways cooperate to maintain pluripotency of human embryonic stem cells. J Cell Sci
118: 4495–4509.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16179608</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van de Laar IM, Oldenburg RA, Pals G, Roos-Hesselink JW, de Graaf BM, Verhagen JM, Hoedemaekers YM, Willemsen R, Severijnen LA, Venselaar H, et al.
2011. 
Mutations in SMAD3 cause a syndromic form of aortic aneurysms and dissections with early-onset osteoarthritis. Nat Genet
43: 121–126.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21217753</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B. 2006. 
TGFβ in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity
24: 179–189.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16473830</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vogel T, Ahrens S, Buttner N, Krieglstein K. 2010. 
Transforming growth factor β promotes neuronal cell fate of mouse cortical and hippocampal progenitors in vitro and in vivo: Identification of Nedd9 as an essential signaling component. Cereb Cortex
20: 661–671.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2820705</ArticleId>
            <ArticleId IdType="pubmed">19587023</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. 2013. 
Cancer genome landscapes. Science
339: 1546–1558.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3749880</ArticleId>
            <ArticleId IdType="pubmed">23539594</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wahl SM, Hunt DA, Wakefield LM, McCartney-Francis N, Wahl LM, Roberts AB, Sporn MB. 1987. 
Transforming growth factor type β induces monocyte chemotaxis and growth factor production. Proc Natl Acad Sci
84: 5788–5792.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC298948</ArticleId>
            <ArticleId IdType="pubmed">2886992</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wilson CA, di Clemente N, Ehrenfels C, Pepinsky RB, Josso N, Vigier B, Cate RL. 1993. 
Müllerian inhibiting substance requires its N-terminal domain for maintenance of biological activity, a novel finding within the transforming growth factor-β superfamily. Mol Endocrinol
7: 247–257.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8469238</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wolfman NM, McPherron AC, Pappano WN, Davies MV, Song K, Tomkinson KN, Wright JF, Zhao L, Sebald SM, Greenspan DS, et al.
2003. 
Activation of latent myostatin by the BMP-1/tolloid family of metalloproteinases. Proc Natl Acad Sci
100: 15842–15846.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC307655</ArticleId>
            <ArticleId IdType="pubmed">14671324</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu SP, Theodorescu D, Kerbel RS, Willson JK, Mulder KM, Humphrey LE, Brattain MG. 1992. 
TGF-β1 is an autocrine-negative growth regulator of human colon carcinoma FET cells in vivo as revealed by transfection of an antisense expression vector. J Cell Biol
116: 187–196.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2289262</ArticleId>
            <ArticleId IdType="pubmed">1730743</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu M, Melichian DS, Chang E, Warner-Blankenship M, Ghosh AK, Varga J. 2009. 
Rosiglitazone abrogates bleomycin-induced scleroderma and blocks profibrotic responses through peroxisome proliferator-activated receptor-γ. Am J Pathol
174: 519–533.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2630560</ArticleId>
            <ArticleId IdType="pubmed">19147827</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang Z, Mu Z, Dabovic B, Jurukovski V, Yu D, Sung J, Xiong X, Munger JS. 2007. 
Absence of integrin-mediated TGFβ1 activation in vivo recapitulates the phenotype of TGFβ1-null mice. J Cell Biol
176: 787–793.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2064053</ArticleId>
            <ArticleId IdType="pubmed">17353357</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yoshinaga K, Obata H, Jurukovski V, Mazzieri R, Chen Y, Zilberberg L, Huso D, Melamed J, Prijatelj P, Todorovic V, et al.
2008. 
Perturbation of transforming growth factor (TGF)-β1 association with latent TGF-β binding protein yields inflammation and tumors. Proc Natl Acad Sci
105: 18758–18763.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2596235</ArticleId>
            <ArticleId IdType="pubmed">19022904</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu J, Shao LE, Lemas V, Yu AL, Vaughan J, Rivier J, Vale W. 1987. 
Importance of FSH-releasing protein and inhibin in erythrodifferentiation. Nature
330: 765–767.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3696240</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zeisberg EM, Tarnavski O, Zeisberg M, Dorfman AL, McMullen JR, Gustafsson E, Chandraker A, Yuan X, Pu WT, Roberts AB, et al.
2007. 
Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat Med
13: 952–961.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17660828</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Y, Feng X, We R, Derynck R. 1996. 
Receptor-associated Mad homologues synergize as effectors of the TGF-β response. Nature
383: 168–172.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8774881</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao J, Shi W, Wang YL, Chen H, Bringas P Jr, Datto MB, Frederick JP, Wang XF, Warburton D. 2002. 
Smad3 deficiency attenuates bleomycin-induced pulmonary fibrosis in mice. Am J Physiol Lung Cell Mol Physiol
282: L585–L593.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11839555</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou X, Wang JL, Lu J, Song Y, Kwak KS, Jiao Q, Rosenfeld R, Chen Q, Boone T, Simonet WS, et al.
2010. 
Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell
142: 531–543.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20723755</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
